A proposal to introduce a “preclinical obesity” diagnosis—intended to make obesity assessment more precise—has set off a global debate over whether the change would clarify care pathways or quietly ration them. As STAT News reported, supporters argue the framework could sharpen clinical decision-making beyond body mass index (BMI) alone, while critics warn it may delay treatment, overlook high-risk conditions like diabetes, and widen inequities in who qualifies for effective therapies.
Why redefine obesity now?
Obesity medicine is in the middle of a technological and therapeutic inflection point. On one hand, BMI remains the most common screening tool in clinics and health systems because it’s fast, cheap, and standardized. On the other, BMI has long been criticized for being an imprecise proxy for health risk, failing to distinguish between muscle and fat mass, ignoring fat distribution, and performing differently across age, sex, and ethnic groups.
That tension has intensified as powerful anti-obesity medications—particularly GLP-1 and related incretin-based drugs—have demonstrated meaningful weight loss and improvements in cardiometabolic markers. Yet these therapies are expensive, supply-constrained in some markets, and variably covered by insurers. When clinical demand outstrips access, the definition of “who has obesity” becomes more than academic: it becomes a gatekeeping mechanism for treatment, reimbursement, and social legitimacy.
The proposed “preclinical obesity” concept is positioned as a way to identify people with excess adiposity who do not yet show overt obesity-related disease—separating a risk state from an established disease state. Proponents see that as more aligned with how medicine labels other conditions (e.g., prediabetes). Critics, however, fear it could function less as an early-warning system and more as a reason to withhold or postpone care.
Precision versus postponement: what’s at stake
In the STAT account, skeptics raise three core concerns. First: delayed intervention. If “clinical obesity” becomes the threshold for aggressive treatment, patients deemed “preclinical” could be counseled to wait—despite evidence that earlier intervention can prevent progression to diabetes, fatty liver disease, sleep apnea, and cardiovascular disease. In a system where appointment time is limited and lifestyle programs are scarce, “watchful waiting” can easily become “no treatment.”
Second: exclusion of diabetes. Any new obesity definition must grapple with the fact that diabetes is both a frequent consequence of excess adiposity and increasingly treated with the same medications used for obesity. If the diagnostic framework doesn’t cleanly incorporate diabetes and related metabolic disease, it risks creating contradictory clinical incentives—where a patient’s eligibility depends more on coding logic than on physiology.
Third: inequities. Obesity-related complications are not evenly distributed. Social determinants—food environments, chronic stress, sleep disruption, exposure to endocrine-disrupting chemicals, neighborhood safety, access to preventive care—shape who progresses from “risk” to “disease.” A diagnostic line that requires demonstrable end-organ impact may unintentionally penalize patients who already face barriers, by making them “prove” disease before receiving help.
What it could mean for clinicians
For healthcare professionals, a new diagnostic category would likely ripple across workflows: screening, documentation, and referral patterns. Primary care clinicians could face increased pressure to document cardiometabolic markers, waist circumference, and functional impairments to support coverage determinations. Specialists—endocrinologists, cardiologists, hepatologists—may see shifts in referral timing as systems try to align treatment with evolving definitions.
There’s also a clinical communication challenge. Labels matter. “Preclinical obesity” might motivate some patients by framing risk as actionable—an opportunity to intervene early. But it could also backfire if patients interpret “preclinical” as “not serious” or “not real,” reinforcing stigma or minimizing the urgency of change. Clinicians would need clear guidance on counseling, including how to discuss benefits and risks of medications, the role of behavioral interventions, and realistic timelines for improvement.
What it could mean for patients and payers
Patients are likely to experience the impact most directly through insurance coverage and access to therapies. In practice, diagnoses often become authorization criteria: a new label could either broaden access (by validating risk states) or narrow it (by restricting reimbursement to “clinical” cases with documented complications). If payers interpret “preclinical” as optional or cosmetic, coverage could shrink—even as demand grows.
At the same time, a more nuanced definition could encourage earlier, lower-intensity interventions: structured nutrition programs, sleep and stress management, anti-stigma counseling, and targeted monitoring of metabolic risk. Done well, that might reduce progression to advanced disease and lower long-term costs. Done poorly, it could create a two-tier system—where well-resourced patients purchase medications out-of-pocket while others are told to wait.
The AI angle: definitions are becoming infrastructure
As health systems deploy AI to identify high-risk patients, definitions like “preclinical obesity” can become embedded into algorithms—shaping outreach lists, clinical decision support, and population health targets. If the label is tied to easily measurable variables (BMI plus labs, imaging, or functional assessments), it could improve risk stratification. But if the criteria reflect biased data or uneven access to diagnostics, AI tools could amplify inequities: patients without frequent lab work, wearable data, or specialty care may be under-identified and under-treated.
In other words, the definition is not just a clinical statement—it becomes digital infrastructure.
Where the debate goes next
The controversy highlighted by STAT News is a reminder that redefining obesity is ultimately a policy decision as much as a medical one. The next phase will likely hinge on how professional societies translate categories into practice guidelines, how insurers operationalize them in prior authorization rules, and whether public health leaders can ensure that earlier identification leads to earlier support—not delayed care.
Expect the conversation to move toward measurable outcomes: Do patients labeled “preclinical” receive more preventive services? Are complication rates reduced? Does access to effective therapies become more equitable—or more restricted? If the new framing can be paired with fair coverage policies and robust preventive programs, it could modernize obesity care. If not, it risks becoming another line on a chart that patients cross only after preventable harm has already occurred.